drugset / Trial / NCT03934450

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450 ↗

Phase 1 Completed 36 enrolled University of Mississippi, Oxford
Non-randomizedCrossoverSingle-blindBasic science

Summary

To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.

Timeline

Start
2018-08-17
Primary completion
2019-05-01
Completion
2019-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Primaquine Small molecule 30 mg —
Comparator Primaquine Small molecule 45 mg —
Subject RPQ Unknown 15 mg —
Subject RPQ Unknown 22.5 mg —
Comparator SPQ Unknown 15 mg —
Comparator SPQ Unknown 22.5 mg —

Indications